Acute myeloid leukemia (AML) isn’t the most commonly known cancer. It is, however, one of the deadliest—an awful rare malignancy of the blood and bone marrow whose victims are already older and frail, ...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell ...
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an ...
The MarketWatch News Department was not involved in the creation of this content. Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and ...
Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel ...
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) CD33 splicing single nucleotide polymorphism was evaluated in ...
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results